[go: up one dir, main page]

EP1694845A1 - Anticorps anticarcinomes et leurs utilisations - Google Patents

Anticorps anticarcinomes et leurs utilisations

Info

Publication number
EP1694845A1
EP1694845A1 EP04761652A EP04761652A EP1694845A1 EP 1694845 A1 EP1694845 A1 EP 1694845A1 EP 04761652 A EP04761652 A EP 04761652A EP 04761652 A EP04761652 A EP 04761652A EP 1694845 A1 EP1694845 A1 EP 1694845A1
Authority
EP
European Patent Office
Prior art keywords
sequence
polypeptide
amino acid
seq
afai
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP04761652A
Other languages
German (de)
English (en)
Other versions
EP1694845A4 (fr
EP1694845B1 (fr
EP1694845B8 (fr
Inventor
Colin Roger Mackenzie
Jianbing Zhang
Thanh-Dung Nguyen
Qinggang Li
Kien Trung Mai
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
National Research Council of Canada
Ottawa Health Research Institute
Original Assignee
Ottawa Health Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ottawa Health Research Institute filed Critical Ottawa Health Research Institute
Priority to PL04761652T priority Critical patent/PL1694845T3/pl
Publication of EP1694845A1 publication Critical patent/EP1694845A1/fr
Publication of EP1694845A4 publication Critical patent/EP1694845A4/fr
Publication of EP1694845B1 publication Critical patent/EP1694845B1/fr
Application granted granted Critical
Publication of EP1694845B8 publication Critical patent/EP1694845B8/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3023—Lung
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6857—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from lung cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3007—Carcino-embryonic Antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Definitions

  • proteomic research will greatly facilitate the discovery of novel tumor targets.
  • Major advances have been made in the identification of targets for diagnostic purposes.
  • limitations of the present technologies have hindered identification of new therapeutic targets.
  • the techniques commonly employed in proteomics such as two-dimensional gel electrophoresis, Liquid Chromatography Tandem Mass Spectrometry (LC/MS/MS), Matrix-Assisted Laser Desorption lonization/Mass Spectrometry (MALDI-MS), and the yeast two-hybrid system have not met the demand for "drugable" targets, such as cell surface markers.
  • Tumor targeting antibodies and peptides can be isolated by library display approaches (e.g. Aina, 2002; Hoogenboom, 1998). This is usually accomplished by screening a phage display library, or libraries with other display formats, against purified tumor specific or tumor associated antigens. However, tumor targeting antibodies and peptides have also been isolated by panning libraries against tumor cells or tumor tissues without prior information on the molecular targets.
  • library display approaches e.g. Aina, 2002; Hoogenboom, 1998. This is usually accomplished by screening a phage display library, or libraries with other display formats, against purified tumor specific or tumor associated antigens.
  • tumor targeting antibodies and peptides have also been isolated by panning libraries against tumor cells or tumor tissues without prior information on the molecular targets.
  • a phage particle displaying an antibody fragment on all copies of pill can be considered a pentavalent antibody.
  • This multivalent display of antibody fragments on phage greatly increases the avidity of the antibody and facilitates both screening and evaluation of phage antibodies.
  • Isolated antibody fragments (scFvs or sdAbs) or peptides bind antigen much less efficiently since they exist primarily in a monovalent form and lack avidity.
  • An antibody fragment oligomerization strategy that permits pentavalency as in pill phage display is the subject of PCT/CA02/01829 (MacKenzie and Zhang). Fusion of a single domain antibody (sdAb) to the homo-pentamerization domain of the B subunit of verotoxin (VT1B) results in the simultaneous pentamerization of the sdAb.
  • the pentavalent sdAbs termed pentabodies, bind much more strongly to immobilized antigen than their monomeric counterparts. In the instance of peptide hormone-binding sdAb, pentamerization resulted in 10 3 to 10 4 -fold improvement in binding to immobilized antigen.
  • a novel single domain antibody AFAI and fragments thereof which has specific affinity for binding to carcinoma, and especially lung carcinoma.
  • This antibody, and portions thereof, can be used, inter alia in the diagnosis and treatment of carcinoma.
  • FIGURE 1 is a depiction of monomeric and pentameric AFAI.
  • AFAI Sequence of AFAI (SEQ ID NO. 1) with CDR1 , CDR2 and CDR3 underlined
  • ES1 Schematic of the primary structures of the monomeric (AFAI) and pentameric (ES1 ) proteins
  • sequence of ES1 SEQ ID NO. 2 with AFAI underlined
  • FIGURE 2 is a pictorial depiction of immunocytochemical staining of A549 cells with the AFAI phage antibody.
  • Cells were exposed to the AFAI phage as the first antibody, mouse anti-M13 IgG as the second antibody and Alexa Fluor 546 labeled goat anti-mouse IgG as the third antibody.
  • DAPI and DiOC ⁇ (3) were used to stain cell nuclei and endoplasmic reticulum, respectively.
  • FIGURE 3 is a pictorial depiction of immunocytochemical staining of A549 with AFAI and ES1.
  • A549 cells were exposed to either ES1 (A) or AFAI (D) as the first antibody, monoclonal anti-c-myc IgG as the second antibody, Alexa Fluor 546 (red) labeled anti-mouse IgG as the third antibody.
  • DAPI staining of (A) and (D) are shown in (B) and (E), respectively.
  • Superimpositions of A, B and D, E are shown in C and F, respectively.
  • FIGURE 4 is a pictorial depiction of immunohistochemical staining showing that ES1 binds strongly to differentiated lung adenocarcinoma and does not bind to most colon adenocarcinomas or to normal lung tissue.
  • A Strong positive staining of a lung adenocarcinoma
  • B enlarged view of the boxed area in (A)
  • C negative staining of a colon adenocarcinoma
  • D negative staining of normal lung tissue.
  • FIGURE 5 is a depiction of bronchiolo-alveolar carcinoma of mucinous type: (A) Immunostaining for ES1 showing diffuse moderate immunoreactivity , mainly along luminal borders; (B) A high magnification of an area in A; (C) Immunostaining forTTFI (DAKO) showing negative immunoreactivity.
  • FIGURE 6 is a depiction of metastatic poorly differentiated lung adenocarcinoma: (A) Immunostaining for ES1 showing diffuse strong immunoreactivity; (B) A high magnification of an area in A; (C) Immunostaining for TTFI showing negative immunoreactivity.
  • FIGURE 7 is a depiction of Lung moderately differentiated adenocarcinoma: (A) Immunostaining for ES1 showing strong immunoreactivity in a focal area adjacent to an area displaying focal weak staining; (B) A high magnification of an area in A. (C) Immunostaining for MIB1 (DAKO) showing remarkable increase in immunoreactivity in an area with strong ES1 immunoreactivity.
  • FIGURE 8 is a depiction of lung poorly differentiated adenocarcinoma: (A) Immunostaining for ES1 showing moderate and extensive immunoreactivity; (B, C) High magnification of area in A. Note the negative immunostaining in the normal bronchial epithelium.
  • FIGURE 9 is a depiction of lung Adeno-squamous carcinoma: (A) Immunostaining for ES1 showing focal immunoreactivity; (B, C) High magnifications of an area in A showing focal immunoreactivity.
  • FIGURE 10 is a depiction of a typical adenomatous hyperplasia of the lung: (A) Immunostaining for ES1 showing focal weak immunoreactivity , (B, C) High magnifications of an area in A showing weak immunoreactivity.
  • FIGURE 11 is a depiction of metastatic moderately differentiated colonic adenocarcinoma in the brain: (A)lmmunostaining for ES1 showing focal immunoreactivity in a few single cells; (B) A high magnification of an area in A.
  • FIGURE 12 is a depiction of infiltrating duct carcinoma of the breast: (A) Immunostaining for ES1 showing focal moderate immunoreactivity; (B) A high magnification of an area in A; (C) Focal strong immunoreactivity in a few acini in normal breast tissue.
  • a novel tumor antigen discovery platform based on screening a single domain antibody (sdAb) library against tumor cells and subsequently identifying the corresponding antigens of the isolated antibodies is described herein.
  • sdAb single domain antibody
  • a specific sdAb, AFAI specific for non-small cell lung carcinoma (A549 cell line) was isolated from a phage library derived from the heavy chain antibody repertoire of a llama as described in Example 1.
  • the homopentamerization property of a non-toxic verotoxin B-subunit was exploited to make the ES1 pentabody, the pentameric forms of AFAI. Pentamerization dramatically improved the binding of the AFAI to A549 cells. Immunohistostaining showed that ES1 is highly specific for lung carcinoma.
  • suitable variants are useful in the diagnosis and treatment of lung carcinoma. Diagnostic methods with which ES1 , AFAI and/or suitable variants thereof can be used include: immunohistochemical methods; labeling the molecule(s) (ES1 , AFAI, variants) with radio isotopes and detecting with tumor imaging tools such as positron emission tomography and MRI; analysis of blood samples (and detecting binding using standard techniques).
  • Diagnostic kits comprising ES1 , AFAI and/or a suitable variant thereof and instructions for their use are specifically contemplated.
  • Therapeutic methods and compositions relating to ES1 and AFAI include employing AFAI, ES1 , or a suitable variant thereof and, for example: labeling them with radio isotope and applying the molecules to a patient; conjugating them to one or more conventional therapeutics and applying the conjugate to a patient; conjugating them to one or more toxins and applying the conjugates to patients; expressing nucleic acid molecules encoding ES1 , AFAI and/or a suitable variant thereof in a gene therapy vector and applying the vectors to patients.
  • the non-small cell lung carcinoma cell line A549 was purchased from ATCC (Manassas, VA) and maintained in DMEM (Gibco, Rockville, MA) supplemented with 5% FBS (Gibco) and 1% Antibiotic-Antimycotic (Gibco).
  • DMEM Gibco, Rockville, MA
  • FBS Gibco
  • Antibiotic-Antimycotic Gibco
  • Primary human dermal fibroblast cells were kindly provided by Dr. J. Xu (Apotex Research Inc. Ottawa, ON).
  • Polyclonal rabbit anti-verotoxin antiserum was kindly provided by Dr. Clifford Lingwood (Univ. of Toronto).
  • a na ⁇ ve llama single domain antibody library (Tanha et al, 2002) served as the source of an antibody fragment specific for tumor cells, in this instance the non-small cell lung carcinoma cell line A549.
  • the isolation of phage antibodies that bind to A549 cells termed cell panning, was performed with A549 cells with pre-adsorption of the library on human fibroblasts at each round of panning.
  • An sdAb phage display library (Tanha et al, 2002) was panned with A549 as the target cells and human dermal fibroblasts as subtracting cells. The panning was performed as described in Becerril et. al. (1999) with slight modifications. For the first round of panning, 10 13 pfu were incubated with the subtracting fibroblast cells to remove fibroblast-binding phage. Phage particles remaining in the supernatant were incubated with A549 cells cultured in a 5 cm petri dish at room temperature for 1 hr.
  • the A549 cells were washed 5 times, 1 minute each, with PBS and 5 times, 10 minutes each, with stripping buffer (50 mM glycine, pH 2.8, 0.5 M NaCI, 2 M urea, 2% polyvinylpyrolidone) and then lysed with 100 mM triethylamine.
  • the cell lysate was neutralized by the addition of 100 ⁇ l of 1M Tris (pH 7.0). Phage in the neutralized cell lysate were amplified in E. coli TG1 cells.
  • the amplified sub-library was subjected to the next round of panning employing the same method. Individual phage clones were selected after four rounds of panning and the DNA sequences encoding the displayed antibodies were determined.
  • Cell Staining Part A Cell staining with phage displayed AFAI When A549 cells were immunostained with AFAI phage as the first antibody followed by an anti-M13 monoclonal antibody and Fluor 546 labeled goat anti-mouse IgG it was observed that very intense fluorescent signals were associated with a cell sub-population (Fig. 2). The staining pattern of the positive A549 cells suggested that AFAI binds to an abundant membrane antigen.
  • a human bronchial epithelial cell line, HBE4, a human prostate cell line, PREP and a primary human fibroblast cell line were chosen as controls for immunocytochemical staining. Under the same conditions employed for A549 immunocytochemistry, no staining was observed with human fibroblasts and only very weak staining was observed with HBE4 and PREP.
  • Example 3 Cell Staining Part B Production of monomeric and pentameric AFAI sdAbs and cell staining with the sdAbs
  • AFAI AFAI-derived neuropeptide-like AFAI
  • Fig. 1B E. coli expression vector
  • ES1 pentameric form of AFAI
  • DNA encoding sdAb AFAI was cloned into the Bbsl/BamHI sites of plasmid pSJF2 (Tanha, 2003) and Bbsl/Apal sites of plasmid pVT2 to generate expression vectors for monomeric and pentavalent AFAI, respectively.
  • the obtained E. coli clones were designated pAFAI (monomer) and pES1 (pentamer). Proteins AFAI and ES1 were produced as described in Tanha et. al. (2003) with the modification of protein extraction from E. coli cells by cell lysis instead of osmotic shock.
  • the pAFAI and pES1 clones were inoculated into 100 ml M9 medium (0.2% glucose, 0.6% Na 2 HPO 4 , 0.3% KH 2 PO 4 , 0.1% NH 4 CI, 0.05% NaCI, 1 mM MgCI 2 , 0.1 mM CaCI 2 ) supplemented with 0.4% casamino acids, 5 mg/l vitamin B1 and 200 ⁇ g/ml ampicillin and shaken overnight at 37 °C. Thirty ml of the overnight M9 culture were transferred into 1 liter of M9 medium with the same supplements and shaken at 37 °C for 24 hours.
  • Induction of gene expression was initiated by the addition of 100 ml 10 x TB nutrients (12% Tryptone, 24% yeast extract, 4% glycerol), 2 ml of 100 mg/ml ampicillin and 1 ml of 1 M IPTG and the cultures were shaken at room temperature for 48 to 72 hours.
  • E. coli cells were harvested by centrifugation and lysed with an EmulsiflexTM Cell Disruptor (Avestin Inc. Ottawa, ON). The cell lysate was centrifuged, the obtained clear supernatant was loaded onto a Hi-TrapTM Chelating Affinity Column (Amersham Biosciences, Piscataway, NJ) and proteins containing Hiss tag were purified following the manufacturer's instructions.
  • Immunochemical staining of A549 cells was performed with both monomeric (AFAI) and pentameric (ES1) antibodies.
  • AFAI AFAI
  • ES1 ES1 pentabody
  • Primary antibodies monoclonal anti-M13 IgG (Amersham Biosciences) for M13 phage or the 9E10 anti c-myc IgG (ATCC) for the ES1 pentabody were applied at a 1 :100 dilution for 30 minutes at room temperature followed by three washes with PBST.
  • the third antibody Alexa Fluor 546-labeled goat anti-mouse IgGTM (Molecular Probes, Inc.
  • ES1 tissue specificity
  • Immunostaining of human tissues using ES1 as the primary antibody was performed using the avidin-biotin peroxidase complex (ABC) method with an ABC kit (Vector Laboratories, Burlingame, CA, USA) on four micron-thick sections cut from the paraffin blocks.
  • ABC avidin-biotin peroxidase complex
  • the immunoreactivity for ES1 was assessed by two pathologists and was scored as moderately or strongly positive staining when there was a continuous membranous and / or cytoplasmic staining pattern and as weakly positive when there was discontinuous membrane or weak cytoplasmic staining.
  • the moderate or strong staining pattern was further scored as 3 in cases showing staining in more than 50%, 2 in more than 10% and 1 in up to 10% of cells. Cases with a discrepant score were reviewed.
  • ES1 displayed moderate to strong immunoreactivity with most lung adenocarcinomas. None of the colon adenocarcinomas displayed strong immunoreactivity with ES1 ; however, weak to moderate focal immunoreactivity was observed in a few cases. Non cancerous lung and colon tissues were not immunoreactive.
  • adenocarcinoma colonic adenocarcinomas including 15 adenocarcinoma colonic adenocarcinomas, 8 breast carcinomas, 4 urothelial carcinomas and adenocarcinomas of the pancreas (six), stomach (six) and gallbladder (one), esophagus (three), urinary bladder (two), ovary (three) and trachea (one), the immunoreactivity was scored as 1 , 2 , 3, weak and negative in 15, 11 , 3, 12 and 12, respectively ( Figures 11 ,12). Colonic adenocarcinomas formed the subgroup of tumor with more diffuse and strong immunoreactivity. Colonic adenomas only displayed focal or weak immunoreactivity.
  • Immunostaining for MIB1 performed on 24 large sections of 24 non- squamous large cell lung carcinomas with score 1 or 2 immunoreactivity showed a remarkable increase in proliferativity of tumor cells in areas of large numbers of ES1 -immunoreactive cells as compared to areas with negative, weak or focal ES1 -immunoreactive cells.
  • the immunostaining for TTFI was performed on microarray tissue. All non-lung and non-thyroid tissue showed negative nuclear immunoreactivity. For 35 lung non-squamous large cell carcinomas, TTF1 immunoreactivity was negative in 8 cases including 5 undifferentiated large cell carcinomas, two poorly-differentiated adenocarcinomas and one mucinous bronchiolo-alveolar carcinoma. The other types of microarray tissue were not immunoreactive.
  • ES1 immunoreactivity was almost completely limited to malignant tumors, particularly lung adenocarcinomas. There was a tendency for the immunoreactivity to be stronger in lung tumors with a mucinous component as non-mucinous bronchiolo-alveolar carcinomas showed only focal immunoreactivity. ES1 immunoreactivity was positive in a number of colonic adenocarcinomas with weaker and more focal staining than in lung adenocarcinomas. Of interest, ES1 immunostaining remained scoring 2 or 3 for undifferentiated large cell lung carcinoma in the primary as well as in the metastatic sites as compared to low sensitivity of TTF1 in the immunostaining of the undifferentiated large cell lung carcinoma (*).
  • colonic adenomas showed only focal weak or negative immunoreactivity.
  • Mucinous adenocarcinoma from other organs displayed score 2, focal or weak immunoreactivity in a small number of cases.
  • the immunoreactive changes identified in the lung adenocarcinomas in this study likely correspond to an up-regulation of the AFAI antigen. This impression is supported by the finding of positive ES1 immunoreactivity in areas of carcinoma of the lung with increased proliferativity as demonstrated by the immunoreactivity for MIB1.
  • AFAI antigen appears to be up-regulated in lung adenocarcinoma, even in less differentiated tumors.
  • ES1 is likely a more sensitive marker for lung poorly differentiated lung adenocarcinoma than TTF1. Since most normal tissue tested were not ES1 -immunoreactive, ES1 is suitable for use in the development of a screening test for lung adenocarcinomas and a number of colon and breast carcinomas.
  • an amino acid sequence of AFAI as shown in Figure 1 or an amino acid sequence at least 90%, 95% or 98% identical to it. Examples of variant amino acid sequences of interest are shown in Table III in which unchanged residues are indicated by a hyphen.
  • AFAI may be mutated at any position which does not interfere with antigen binding or specificity.
  • Sites of particular interest include those for which some possible mutations are shown in Table III. While only some possible variants are shown, it will be appreciated that all functional variants, including all variants of AFAI differing from SEQ. ID. No. 1 by one or more of the amino acid changes depicted in Table III are specifically contemplated and fall within the scope of the invention.
  • an amino acid sequence having complete sequence identity to the underlined (CDR) regions of AFAI as shown in Figure 1 and having at least 40%, 60%, 80%, or 90% sequence identity to the remaining portions of that sequence.
  • nucleic acid sequences encoding such amino acid sequences.
  • nucleic acid sequences encoding AFAI as disclosed in Figure 1 , or an amino acid sequence at least 90% or 95% identical to it.
  • a nucleic acid sequence encoding a protein which has at least 70%, 80%, 90% 95%, or 98% sequence identity to the sequence of AFAI or ES1 as depicted in Table 2, or to a continuous 250 nucleic acid region thereof, or being complementary to any such nucleic acid sequence.
  • PCR primers suitable for the amplification of a nucleic acid encoding AFAI or a portion thereof. In some instances the portion will include at least one CDR region.
  • polypeptide sequence comprising at least 90 amino acids including at least one of the following three contiguous amino acid sequences: KNLMG, TISGSGGTNYASSVEG, and AFAI.
  • KNLMG TISGSGGTNYASSVEG
  • AFAI AFAI
  • AFAI-derived polypeptide and/or a polypeptide having at least 90% identity to SEQ ID NO. 1 and/or a portion thereof in forming a conjugate by grafting the polypeptide to an antigen binding fragment In some instances one or more of the AFAI CDR's is grafted onto an antigen binding fragment including, for example, a VHH, VH or VL framework (scaffold) or an immunoglobin and/or fragment thereof (e.g. Fab, scFv).
  • One or more AFAI CDR's may also be used to produce a fusion protein wherein the second polypeptide sequence provides a useful functionality or property. In some instances it may be desired to produce humanized variants of the AFAI antibody using techniques known in the art.
  • Such humanized antibodies are specifically contemplated herein.
  • the cargo molecule may be useful for diagnosis or treatment of carcinoma.
  • it may be an enzyme or radioisotope useful in the identification and localization of cells of interest in tissue or it may be a cytotoxic agent such as a drug, further strong antigen, apoptosis inducer or radioisotope useful in reducing the viability or ability to proliferate of a carcinoma cell.
  • a cytotoxic agent such as a drug, further strong antigen, apoptosis inducer or radioisotope useful in reducing the viability or ability to proliferate of a carcinoma cell.
  • Table 1 143 neoplastic lesions and 103 samples of non-neoplastic different tissue

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention porte sur la séquence d'acides aminés: X1,VQPGGSLRL SCAAHDPIFD KNLMGWX2RQA PGKX3X4EX5VAT ISGSGGTNYA SSVEGRFTIS RDNAKKTVYL QMNDLKPEDT AVYYCNSAFA IX6GQGTQVTV SS, dans laquelle: Xl est: V, S, D, L, F, W, ou T; X2 est: G, F, Y, V, I, H, ou L; X3 is: Q, G, E, D, L, R, ou K; X4 est: R, C, Q, L, I, P, ou K; X5 est: Y, T, A, W, F, S, ou L; et X6 est: W, R, E, A, G, V, ou K. Cette séquence est utile pour la production d'anticorps et d'autres protéines, capables de reconnaître les antigènes spécifiques du cancer.
EP04761652.9A 2003-11-28 2004-08-17 Anticorps anticarcinomes et leurs utilisations Expired - Lifetime EP1694845B8 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PL04761652T PL1694845T3 (pl) 2003-11-28 2004-08-17 Przeciwciała przeciwko rakowi i ich zastosowania

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US52518303P 2003-11-28 2003-11-28
PCT/CA2004/001488 WO2005052158A1 (fr) 2003-11-28 2004-08-17 Anticorps anticarcinomes et leurs utilisations

Publications (4)

Publication Number Publication Date
EP1694845A1 true EP1694845A1 (fr) 2006-08-30
EP1694845A4 EP1694845A4 (fr) 2008-07-02
EP1694845B1 EP1694845B1 (fr) 2017-07-05
EP1694845B8 EP1694845B8 (fr) 2017-12-20

Family

ID=34632969

Family Applications (1)

Application Number Title Priority Date Filing Date
EP04761652.9A Expired - Lifetime EP1694845B8 (fr) 2003-11-28 2004-08-17 Anticorps anticarcinomes et leurs utilisations

Country Status (8)

Country Link
US (1) US7872105B2 (fr)
EP (1) EP1694845B8 (fr)
JP (1) JP5618453B2 (fr)
AU (1) AU2004293502B2 (fr)
CA (1) CA2547034C (fr)
ES (1) ES2642565T3 (fr)
PL (1) PL1694845T3 (fr)
WO (1) WO2005052158A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007124133A2 (fr) 2006-04-20 2007-11-01 The Henry M. Jackson Foundation For The Advancement Of Military Medicine Incorporated Procédés et compositions à base de la protéine toxine de shiga de type 1
EP2381954B8 (fr) 2009-01-23 2017-01-25 The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. Méthodes et compositions basées sur la protéine shiga-toxine de type 2
RU2689689C2 (ru) * 2015-01-23 2019-05-28 Хеликс Байофарма Корпорейшн Конъюгаты антитело-уреаза для терапевтических целей
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5593847A (en) * 1991-12-30 1997-01-14 Bayer Corporation Monitoring of NC 50/90 in blood samples of breast cancer patients
US5777078A (en) * 1993-04-28 1998-07-07 Worcester Foundation For Experimental Biology Triggered pore-forming agents
JPH09500102A (ja) * 1993-04-28 1997-01-07 ウォーセスター ファウンデーション フォー エクスペリメンタル バイオロジー 細胞指向性溶解孔形成剤
US5874298A (en) * 1995-02-17 1999-02-23 Nps Pharmaceuticals, Inc. Insecticidal toxins from Bracon hebetor nucleic acid encoding said toxin and methods of use
US6190657B1 (en) * 1995-06-07 2001-02-20 Yale University Vectors for the diagnosis and treatment of solid tumors including melanoma
GB9621295D0 (en) * 1995-12-07 1996-11-27 Cambridge Antibody Tech Specific binding members,materials and methods
US5798218A (en) * 1996-09-24 1998-08-25 University Of British Columbia Innovation And Development Corporation Compositions and methods for the specific detection of thy-1 antigen
AU716564B2 (en) 1996-11-06 2000-03-02 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Protease-activatable pseudomonas exotoxin A-like proproteins
ES2243240T3 (es) * 1999-03-01 2005-12-01 Genentech, Inc. Anticuerpos para la terapia y diagnostico del cancer.
AU3767300A (en) * 1999-03-26 2000-10-16 Human Genome Sciences, Inc. 47 human secreted proteins
WO2001054732A1 (fr) * 2000-01-27 2001-08-02 Genetics Institute, Llc. Anticorps contre ctla4 (cd152), conjugues comprenant lesdits anticorps, et leurs utilisations
WO2001085777A2 (fr) 2000-05-09 2001-11-15 Greenville Hospital System Peptides therapeutiques formant des pores
US7456146B2 (en) * 2001-05-09 2008-11-25 Ghc Research Development Corporation Lytic peptide prodrugs
EP1402152B1 (fr) * 2001-07-03 2007-01-17 ABB Turbo Systems AG Systeme de retenue pour des aubes mobiles de turbomachines a ecoulement axial
ES2542888T3 (es) 2001-08-24 2015-08-12 Uvic Industry Partnerships Inc. Proaerolisina que contiene secuencias de activación de proteasa y métodos de uso para el tratamiento del cáncer de próstata
WO2003048304A2 (fr) 2001-11-29 2003-06-12 Wyeth Holdings Corporation Cadres de lecture ouverts (orf) de la bacterie alloiococcus otitidis codant des polypeptides antigeniques, compositions imunogenes, et leurs utilisations
MXPA04005134A (es) * 2001-11-30 2004-08-11 Ca Nat Research Council Novedosas moleculas de auto-montaje.
EP1461085A2 (fr) * 2002-01-03 2004-09-29 Vlaams Interuniversitair Instituut voor Biotechnologie vzw. Immunoconjugues utiles pour le traitement de tumeurs
US20060159687A1 (en) * 2003-03-03 2006-07-20 Buckley J T Modified aerolysin and methods of use for treating lung cancer

Also Published As

Publication number Publication date
CA2547034A1 (fr) 2005-06-09
WO2005052158A1 (fr) 2005-06-09
AU2004293502A1 (en) 2005-06-09
JP5618453B2 (ja) 2014-11-05
AU2004293502B2 (en) 2010-12-02
ES2642565T3 (es) 2017-11-16
US20060286113A1 (en) 2006-12-21
EP1694845A4 (fr) 2008-07-02
US7872105B2 (en) 2011-01-18
PL1694845T3 (pl) 2019-01-31
JP2008501304A (ja) 2008-01-24
EP1694845B1 (fr) 2017-07-05
CA2547034C (fr) 2014-02-18
EP1694845B8 (fr) 2017-12-20

Similar Documents

Publication Publication Date Title
Zhang et al. A pentavalent single-domain antibody approach to tumor antigen discovery and the development of novel proteomics reagents
US9629801B2 (en) Blood-brain barrier targeting antibodies
CA2813133C (fr) Anticorps anti-ceacam6 et leurs utilisations
Bidlingmaier et al. Identification of MCAM/CD146 as the target antigen of a human monoclonal antibody that recognizes both epithelioid and sarcomatoid types of mesothelioma
US10738115B2 (en) Humanized antibodies transmigrating the blood-brain barrier and uses thereof
KR102355310B1 (ko) 인슐린-유사 성장 인자 1 수용체-특이적 항체 및 그의 용도
US20100092470A1 (en) Antibodies, analogs and uses thereof
US8591893B2 (en) Paratope and epitope of anti-mortalin antibody
KR102355308B1 (ko) 인슐린-유사 성장 인자 1 수용체-특이적 항체 및 그의 용도
CN108084265B (zh) 特异性结合人的5t4抗原的全人源单域抗体及其应用
KR101732553B1 (ko) 활성화된 ras 특이적인 항체의 중쇄가변영역 및 그의 이용
NZ518300A (en) Novel compounds
US20170015748A1 (en) Insulin-like growth factor 1 receptor -specific antibodies and uses thereof
Könning et al. Isolation of a pH-sensitive IgNAR variable domain from a yeast-displayed, histidine-doped master library
WO2021157601A1 (fr) Anticorps anti-meflin destiné à être utilisé dans le traitement du cancer chez un sujet atteint d'un cancer, et composition pharmaceutique comprenant ledit anticorps
Aghamollaei et al. Isolation and characterization of a novel nanobody for detection of GRP78 expressing cancer cells
KR20140019284A (ko) 항-C-Met 항체 및 이의 이용 방법들
CA2547034C (fr) Anticorps anticarcinomes et leurs utilisations
CN119923407A (zh) 靶向人淋巴细胞抗原6家族成员k（ly6k）的三种抗体候选物的抗体序列
WO2017155355A1 (fr) Anticorps se liant spécifiquement à la protéine aimp2-dx2
Zhang et al. A coiled coil-based pre-targeting drug delivery system for precise treatment of breast cancer
CN113788896A (zh) 抗msln单克隆内化抗体及其制备方法和应用
EP4317549A1 (fr) Vecteur et procédé de criblage de protéine fonctionnelle de liaison à un antigène
CN119899268A (zh) 一种抗NKp46的纳米抗体及其应用
Salavatifar et al. Green fluorescent-conjugated anti-CEA single chain antibody for the detection of CEA-positive cancer cells

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20060629

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

R17P Request for examination filed (corrected)

Effective date: 20060628

DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: G01N 33/574 20060101ALI20080522BHEP

Ipc: C12N 15/13 20060101ALI20080522BHEP

Ipc: C07K 19/00 20060101ALI20080522BHEP

Ipc: A61K 47/48 20060101AFI20080522BHEP

Ipc: C07K 16/30 20060101ALI20080522BHEP

Ipc: C07K 14/245 20060101ALI20080522BHEP

Ipc: A61P 35/00 20060101ALI20080522BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20080530

17Q First examination report despatched

Effective date: 20081103

APBK Appeal reference recorded

Free format text: ORIGINAL CODE: EPIDOSNREFNE

APBN Date of receipt of notice of appeal recorded

Free format text: ORIGINAL CODE: EPIDOSNNOA2E

APBR Date of receipt of statement of grounds of appeal recorded

Free format text: ORIGINAL CODE: EPIDOSNNOA3E

APAV Appeal reference deleted

Free format text: ORIGINAL CODE: EPIDOSDREFNE

APAF Appeal reference modified

Free format text: ORIGINAL CODE: EPIDOSCREFNE

APBX Invitation to file observations in appeal sent

Free format text: ORIGINAL CODE: EPIDOSNOBA2E

APBF Information on invitation to file observation in appeal deleted

Free format text: ORIGINAL CODE: EPIDOSDOBA2E

APBT Appeal procedure closed

Free format text: ORIGINAL CODE: EPIDOSNNOA9E

REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Ref document number: 602004051495

Country of ref document: DE

Free format text: PREVIOUS MAIN CLASS: C12N0015130000

Ipc: A61K0047680000

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20170116

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 47/68 20170101AFI20170113BHEP

Ipc: G01N 33/574 20060101ALI20170113BHEP

Ipc: C12N 15/13 20060101ALI20170113BHEP

Ipc: C07K 19/00 20060101ALI20170113BHEP

Ipc: C07K 14/245 20060101ALI20170113BHEP

Ipc: C07K 16/30 20060101ALI20170113BHEP

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R081

Ref document number: 602004051495

Country of ref document: DE

Owner name: OTTAWA HOSPITAL RESEARCH INSTITUTE, OTTAWA, CA

Free format text: FORMER OWNER: OTTAWA HEALTH RESEARCH INSTITUTE, OTTAWA, ONTARIO, CA

Ref country code: DE

Ref legal event code: R081

Ref document number: 602004051495

Country of ref document: DE

Owner name: NATIONAL RESEARCH COUNCIL OF CANADA, OTTAWA, CA

Free format text: FORMER OWNER: OTTAWA HEALTH RESEARCH INSTITUTE, OTTAWA, ONTARIO, CA

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 906127

Country of ref document: AT

Kind code of ref document: T

Effective date: 20170715

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602004051495

Country of ref document: DE

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 14

GRAT Correction requested after decision to grant or after decision to maintain patent in amended form

Free format text: ORIGINAL CODE: EPIDOSNCDEC

REG Reference to a national code

Ref country code: NL

Ref legal event code: FP

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

Ref country code: DE

Ref legal event code: R082

Ref document number: 602004051495

Country of ref document: DE

Representative=s name: FLEUCHAUS & GALLO PARTNERSCHAFT MBB PATENTANWA, DE

Ref country code: DE

Ref legal event code: R082

Ref document number: 602004051495

Country of ref document: DE

Representative=s name: FLEUCHAUS & GALLO PARTNERSCHAFT MBB, DE

Ref country code: DE

Ref legal event code: R081

Ref document number: 602004051495

Country of ref document: DE

Owner name: NATIONAL RESEARCH COUNCIL OF CANADA, OTTAWA, CA

Free format text: FORMER OWNER: OTTAWA HEALTH RESEARCH INSTITUTE, OTTAWA, ONTARIO, CA

Ref country code: DE

Ref legal event code: R081

Ref document number: 602004051495

Country of ref document: DE

Owner name: OTTAWA HOSPITAL RESEARCH INSTITUTE, OTTAWA, CA

Free format text: FORMER OWNER: OTTAWA HEALTH RESEARCH INSTITUTE, OTTAWA, ONTARIO, CA

RAP2 Party data changed (patent owner data changed or rights of a patent transferred)

Owner name: OTTAWA HEALTH RESEARCH INSTITUTE

Owner name: NATIONAL RESEARCH COUNCIL OF CANADA

RAP2 Party data changed (patent owner data changed or rights of a patent transferred)

Owner name: OTTAWA HEALTH RESEARCH INSTITUTE

Owner name: NATIONAL RESEARCH COUNCIL OF CANADA

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2642565

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20171116

REG Reference to a national code

Ref country code: CH

Ref legal event code: PK

Free format text: BERICHTIGUNG INHABER

REG Reference to a national code

Ref country code: DE

Ref legal event code: R082

Ref document number: 602004051495

Country of ref document: DE

Representative=s name: FLEUCHAUS & GALLO PARTNERSCHAFT MBB PATENTANWA, DE

Ref country code: DE

Ref legal event code: R082

Ref document number: 602004051495

Country of ref document: DE

Representative=s name: FLEUCHAUS & GALLO PARTNERSCHAFT MBB, DE

Ref country code: DE

Ref legal event code: R081

Ref document number: 602004051495

Country of ref document: DE

Owner name: OTTAWA HOSPITAL RESEARCH INSTITUTE, OTTAWA, CA

Free format text: FORMER OWNERS: OTTAWA HEALTH RESEARCH INSTITUTE, OTTAWA, ONTARIO, CA; NATIONAL RESEARCH COUNCIL OF CANADA, OTTAWA, ONTARIO, CA

Ref country code: DE

Ref legal event code: R081

Ref document number: 602004051495

Country of ref document: DE

Owner name: NATIONAL RESEARCH COUNCIL OF CANADA, OTTAWA, CA

Free format text: FORMER OWNERS: OTTAWA HEALTH RESEARCH INSTITUTE, OTTAWA, ONTARIO, CA; NATIONAL RESEARCH COUNCIL OF CANADA, OTTAWA, ONTARIO, CA

REG Reference to a national code

Ref country code: CH

Ref legal event code: PFA

Owner name: NATIONAL RESEARCH COUNCIL OF CANADA, CA

Free format text: FORMER OWNER: OTTAWA HEALTH RESEARCH INSTITUTE, CA

RAP2 Party data changed (patent owner data changed or rights of a patent transferred)

Owner name: OTTAWA HOSPITAL RESEARCH INSTITUTE

Owner name: NATIONAL RESEARCH COUNCIL OF CANADA

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170705

REG Reference to a national code

Ref country code: NL

Ref legal event code: HC

Owner name: NATIONAL RESEARCH COUNCIL OF CANADA; CA

Free format text: DETAILS ASSIGNMENT: CHANGE OF OWNER(S), CHANGE OF OWNER(S) NAME; FORMER OWNER NAME: OTTAWA HEALTH RESEARCH INSTITUTE

Effective date: 20180102

REG Reference to a national code

Ref country code: BE

Ref legal event code: HC

Owner name: NATIONAL RESEARCH COUNCIL OF CANADA; CA

Free format text: DETAILS ASSIGNMENT: CHANGE OF OWNER(S), CHANGEMENT DE NOM DU PROPRIETAIRE, NOM/ADRESSE; FORMER OWNER NAME: NATIONAL RESEARCH COUNCIL OF CANADA

Effective date: 20180104

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171006

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171005

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602004051495

Country of ref document: DE

REG Reference to a national code

Ref country code: AT

Ref legal event code: MM01

Ref document number: 906127

Country of ref document: AT

Kind code of ref document: T

Effective date: 20170817

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170705

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170705

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170705

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170705

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170705

Ref country code: AT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170817

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170705

26N No opposition filed

Effective date: 20180406

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170817

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 15

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170705

REG Reference to a national code

Ref country code: AT

Ref legal event code: EK

Ref document number: 906127

Country of ref document: AT

Kind code of ref document: T

Effective date: 20180906

REG Reference to a national code

Ref country code: AT

Ref legal event code: UEP

Ref document number: 906127

Country of ref document: AT

Kind code of ref document: T

Effective date: 20170705

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20040817

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170705

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170705

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170705

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20230825

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20230822

Year of fee payment: 20

Ref country code: IE

Payment date: 20230818

Year of fee payment: 20

Ref country code: GB

Payment date: 20230822

Year of fee payment: 20

Ref country code: ES

Payment date: 20230914

Year of fee payment: 20

Ref country code: CH

Payment date: 20230902

Year of fee payment: 20

Ref country code: AT

Payment date: 20230818

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 20230823

Year of fee payment: 20

Ref country code: PL

Payment date: 20230811

Year of fee payment: 20

Ref country code: FR

Payment date: 20230824

Year of fee payment: 20

Ref country code: DE

Payment date: 20230807

Year of fee payment: 20

Ref country code: BE

Payment date: 20230825

Year of fee payment: 20

REG Reference to a national code

Ref country code: DE

Ref legal event code: R071

Ref document number: 602004051495

Country of ref document: DE

REG Reference to a national code

Ref country code: NL

Ref legal event code: MK

Effective date: 20240816

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20240826

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: BE

Ref legal event code: MK

Effective date: 20240817

REG Reference to a national code

Ref country code: GB

Ref legal event code: PE20

Expiry date: 20240816

REG Reference to a national code

Ref country code: IE

Ref legal event code: MK9A

REG Reference to a national code

Ref country code: SE

Ref legal event code: EUG

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20240817

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20240816

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK07

Ref document number: 906127

Country of ref document: AT

Kind code of ref document: T

Effective date: 20240817

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20240818

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20240817

Ref country code: GB

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20240816

Ref country code: ES

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20240818